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Abstract 
Recent years have seen increasing recognition of a subgroup of inherited platelet function 
disorders which are due to defects in transcription factors that are required to regulate 
megakaryopoiesis and platelet production. Thus, germline mutations in the genes encoding 
the haematopoietic transcription factors RUNX1, GATA-1, FLI1, GFI1b and ETV6 have been 
associated with both quantitative and qualitative platelet abnormalities, and variable bleeding 
symptoms in the affected patients. Some of the transcription factor defects are also associated 
with an increased predisposition to haematologic malignancies (RUNX1, ETV6), abnormal 
erythropoiesis (GATA-1, GFI1b, ETV6) and immune dysfunction (FLI1). The persistence of 
MYH10 expression in platelets is a surrogate marker for FLI1 and RUNX1 defects. 
Characterisation of the transcription factor defects that give rise to platelet function disorders, 
and of the genes that are differentially regulated as a result, are yielding insights into the roles 
of these genes in platelet formation and function.  
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1. Introduction  
Inherited platelet disorders, accompanied by normal or reduced platelet counts, account for a 
significant proportion of bleeding diatheses and have been defined historically according to 
whether the major feature was a quantitative abnormality affecting the platelet count, or a 
qualitative abnormality affecting platelet function. Over the last 15 years, however, 
characterisation of the underlying genetic causes of many platelet disorders has allowed better 
discrimination between these disorders, and classification based on whether the abnormality 
affects platelet adhesion, platelet receptor signalling, platelet secretion, the platelet 
cytoskeleton, platelet procoagulant activity and, or platelet production.1,2 The application of 
next generation sequencing technology for whole exome or genome analysis is facilitating 
identification of further underlying genetic defects in patients with previously unexplained 
platelet disorders.3 Indeed, this approach has been used in the investigation of an interesting 
group of platelet disorders caused by defects in transcription factors which are required to 
regulate megakaryopoiesis, and platelet production, and which can result in both quantitative 
and qualitative platelet abnormalities.4 Notably, the number of transcription factor defects 
identified in patients with platelet function disorders is growing and these appear to account 
for a significant number of cases.  
In this review, the processes involved in megakaryocyte development and platelet production 
will be outlined briefly before focusing on those transcription factors that are required to 
regulate megakaryopoiesis and which have been shown to harbour mutations in patients with 
platelet disorders.    
2. Megakaryopoiesis and platelet production  
Like other blood cells, megakaryocytes are derived from pluripotent haematopoietic stem cells 
(HSCs) that reside mainly in the bone marrow and undergo differentiation through discrete 
steps to give rise to increasingly committed progenitors, including the bipotent megakaryocyte-
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erythroid progenitors (MEPs) which are the precursors of cells of both the erythroid and 
megakaryocytic lineages.5 Under the regulation of thrombopoietin (TPO), early 
megakaryocytes undergo a proliferative stage during which progression through the cell cycle 
is identical to that of other HSCs. This is followed by several rounds of endomitosis where the 
diploid promegakaryocytes undergo DNA replication without cell division, to accumulate a 
DNA content of 4N up to 128N in a multilobular nucleus.6 Following nuclear polyploidization, 
further maturation of the megakaryocytes is accompanied by formation of an extensive 
invaginated membrane system, which is continuous with the plasma membrane and 
permeates the cytoplasm and is thought to act as a membrane reservoir that supports 
proplatelet formation.6,7 It is also characterised by the development of alpha (D) and dense (G) 
storage granules in the cytosol and by the expression of cell surface receptors that mediate 
platelet adhesion and aggregation.8 Thus, megakaryocytes mature into large cells of 150 PM 
or more in diameter which contain all the necessary cellular machinery for functioning 
platelets. It is thought that endomitosis occurs during megakaryopoiesis in order to support 
the protein and membrane synthesis required for production of platelets, through functional 
amplification of the genome,9 and indeed there is some evidence for a correlation between the 
extent of ploidy of megakaryocytes and the number of platelets that they produce.10 
The precise mechanism by which platelets are derived from megakaryocytes is not fully 
understood, but the widely accepted model is one in which the megakaryocytes develop 
multiple, long, branching processes, known as proplatelets, which are decorated along their 
lengths by platelet-sized, bead-like swellings that are connected by cytoplasmic bridges.8 The 
proplatelets extend into the sinusoidal blood vessels of the bone marrow, where the blood flow 
results in release of their terminal buds into the circulation as platelets. In this way, each 
megakaryocyte is estimated to release in the region of 104 platelets into the circulation,11 with 
the average human producing approximately 1011 platelets daily.12 
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The formation of proplatelets is a microtubule-driven process, and normal microtubule function 
is essential to support elongation of the proplatelet branches and accumulation of platelet 
granules and other cellular components in the proplatelet buds. The importance of 
microtubules to thrombopoiesis is evidenced by the block in proplatelet production that occurs 
when megakaryocytes are treated with drugs that disrupt microtubule assembly.13 Similarly, 
mutations in the genes encoding tubulin,14±16 or affecting myosin IIa activity are associated 
with macrothrombocytopenia.17,18  
3. Role of platelets in primary haemostasis 
Once released into the circulation, platelets have an average lifespan of 9 days and do not 
interact significantly with the endothelium within the intact vasculature. However, when blood 
vessel damage leads to exposure of the subendothelial matrix, platelets rapidly accumulate at 
the site of injury to mediate formation of a fibrin-rich platelet plug that stems bleeding into the 
surrounding tissue.19 The initial interactions between platelets and the subendothelium are 
determined to a large extent by the location of the injury. In areas of low shear, such as in 
veins and larger arteries, platelet adhesion is mediated primarily by direct interaction of platelet 
receptors with exposed collagen and other adhesive proteins. In areas of high shear, such as 
in small arteries and the microvasculature, the platelet glycoprotein (GP) Ib-IX-V receptor 
complex mediates tethering of platelets to the site of injury through von Willebrand factor 
(VWF) which is bound to collagen in the extracellular matrix. This interaction allows more 
stable adhesion of platelets through engagement of their GPVI and integrin D2E1 collagen 
receptors, triggering intracellular signalling pathways that lead to changes in intracellular free 
calcium, remodelling of the platelet cytoskeleton, and aggregation of platelets through 
crosslinking of the activated integrin DIIbE3 receptors on different platelets via fibrinogen.19 
Fusion of the intracellular secretory granules of the platelets with the outer platelet membrane 
and the controlled release of their contents into the local environment also occur mediating 
further platelet activation and responses with other cells.20  
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4. Transcription factors are key regulators of platelet formation  
Transcription factors and their co-activators regulate lineage-specific gene expression during 
haematopoiesis by binding to cis-regulatory elements located upstream of the promoter of 
specific target genes to either activate or repress transcription. Knowledge of the key 
regulatory role of transcription factors in the lineage decisions involved in megakaryopoiesis 
and platelet production has expanded rapidly in recent years largely as a result of the 
development of procedures that allow the growth and differentiation of megakaryocytes from 
HSCs in vitro, and also characterisation of the roles of specific transcription factors by mutating 
the corresponding genes in mice. More recently, the identification of patients with defects in 
transcription factor genes that result in disturbances in platelet number and function have 
provided insights into their role in platelet formation and function. Thus, germline mutations 
affecting the haematopoietic transcription factors RUNX1, GATA-1, FLI1, GFI1b and ETV6 
have been shown to result in platelet dysfunction, thrombocytopenia and variable bleeding 
symptoms in patients. The roles of these five transcription factors in haematopoiesis will be 
briefly described (Fig. 1)21, and the germline defects that have been identified in these genes 
will be summarised in the remainder of this review.  
4.1 RUNX1 
4.1.1 Structure and function of RUNX1  
Runt-related transcription factor-1, or RUNX1 (also known as core binding factor alpha, CBFD, 
or acute myeloid leukaemia 1, AML1) is one of three RUNX family members seen in mammals, 
which binds CBFE to form the heterodimeric core binding factor (CBF) transcription complex. 
In humans, heterozygous germline defects in RUNX1 are associated with Familial Platelet 
Disorder with predisposition to Acute Myeloid Leukaemia (FPD/AML; MIM 601399). The 
RUNX1 gene, RUNX1, is located at chromosome 21q22.12 and comprises eight exons. 
Alternative splicing gives rise to at least three RUNX1 variants which differ in size. The largest 
and least abundant variant, RUNX1c, comprises 480 amino acids and differs from RUNX1b 
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by having a distinct 27 amino acid N-terminal region. There is no apparent difference in 
function between RUNX1b and RUNX1c. The smallest variant, RUNX1a, comprises 250 
amino acids and has a similar N-terminal region to RUNX1b, but differs in the C-terminal 
region.22±24 For ease of reference, amino acid residues in RUNX1 are numbered here 
according to the RUNX1b sequence (Fig. 2). All three isoforms share a well characterized 128 
amino acid Runt domain, which is necessary for binding to CBFE and also to the consensus 
sequence ¶-PyGPyGGTPy-¶ in DNA.25 The structure of the Runt domain has been solved 
and the regions that interact with CBFE and DNA have been shown not to overlap. The 
interaction with CBFE increases DNA binding of RUNX1 by stabilizing the Runt domain in a 
high affinity DNA binding conformation. The C-terminal regions of RUNX1b and RUNX1c also 
encompass a transactivation domain which harbours a nuclear matrix-targeting signal and is 
essential for in vivo function, an inhibitory domain, a proline rich PY motif that allows interaction 
with WW domain-containing proteins and a C-terminal VWRPY motif that it is thought to be 
involved in transcription repression.26  
RUNX1 is critical for definitive haematopoiesis, and knockout of the mouse Runx1 gene is 
lethal in utero. Conditional deletion of the gene also demonstrated an essential role for RUNX1 
in megakaryopoiesis, with megakaryocytes showing a reduction in polyploidization and 
cytoplasmic development.27 RUNX1-mediated downregulation of non-muscle myosin IIB 
heavy chain (MYH10) is required for the switch from mitosis to endomitosis that occurs during 
megakaryocyte differentiation,28 and persistence of MYH10 in platelets is a biomarker for 
FPD/AML, and for thrombocytopenia due to deletion of the transcription factor FLI1.29 By itself, 
RUNX1 is not considered to be a strong transcriptional regulator. However, through its 
synergistic interactions with other transcription factors, it exerts strong transcriptional 
activation or repression. For example, it co-operates with the transcription factors GATA-1 and 
FLI-1 to promote megakaryocyte differentiation,30,31 and with C/EBP factors to activate the 
macrophage colony-stimulating factor receptor promoter,32 and several proteins have been 
identified that interact with motifs in the C terminus of RUNX1 to mediate its activities.27  
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4.1.2 RUNX1 and inherited platelet dysfunction 
The autosomal dominant bleeding disorder known as FPD/AML was first described by Dowton 
et al in a large French-Canadian family. The predominant feature of the disorder was a mild 
to moderate thrombocytopenia which was also associated with a prolonged bleeding time.33 
Platelets from the affected family members showed reduced aggregation in response to 
collagen and epinephrine, but aggregated normally in response to ADP and ristocetin. The 
platelet abnormality was associated with haematologic neoplasms in several members of the 
family. Subsequent linkage studies in six further families displaying a phenotype similar to that 
described by Dowton et al, identified a locus on chromosome 21q, and analysis of candidate 
genes in this region identified nonsense defects or intragenic deletions affecting RUNX1 in 
affected members of four families, while missense defects predicting amino acid substitution 
of two conserved amino acids in RUNX1 (p.Arg139Gln and p.Arg174Gln) were identified in 
the remaining two families.34 The effects of the RUNX1 defects on megakaryocyte growth 
were examined by culturing megakaryocytes from peripheral blood and bone marrow from 
affected members of two of the families, which revealed a reduction in megakaryocyte colony 
size and formation compared to the controls. Thus haploinsufficiency of RUNX1 was proposed 
to be the underlying cause of the platelet defect, and to predispose to the acquisition of further 
somatic mutations that cause leukaemia.34  
The recognition of FPD/AML increased awareness of the condition and led to an increase in 
the number of cases reported, allowing better understanding of the clinical expression and 
molecular pathogenesis of the disorder. Several germline RUNX1 defects have been 
identified, the majority affecting regions encoding the Runt domain though a nonsense defect 
occurring outside of the Runt domain has also been identified, p.Y260X.35 Review of the 
literature in 2011 revealed the clinical presentation of FPD/AML to be highly variable, patients 
usually presenting with mild to moderate bleeding symptoms which first appear during 
childhood, and which are characterised by quantitative and, or, qualitative platelet defects, 
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and mild thrombocytopenia with normal sized platelets. However, many patients have no 
bleeding tendency and thrombocytopenia is not always a feature.36  
4.1.3 Explaining the platelet disorders caused by RUNX1 defects 
Several aspects of megakaryopoiesis and platelet function are known to be impaired in 
FPD/AML. Investigation of the ability of TPO to promote megakaryocyte maturation through 
its receptor c-Mpl in a patient with a p.Thr219Argfs* RUNX1 defect revealed elevated levels 
of TPO in the patient, while expression of c-Mpl was reduced and TPO signalling was 
impaired. Levels of MPL mRNA were also lower in platelets from the patient than in wild-type 
platelets. The identification of several potential RUNX1 binding sites in the MPL promoter 
suggested that MPL is a target for RUNX1 and that mutations in RUNX1 are likely to result in 
a reduction in MPL expression, which would contribute to the thrombocytopenia in affected 
patients.37 More recently, further investigation of platelets from carriers of the pThr219Argfs* 
RUNX1 defect, revealed a decrease in platelet aggregation, impaired DIIbE3 activation and 
reducedD- and G-granule content. Decreased expression of the transcription factor p45 NF-
E2, which is essential for DIIbE3 inside-out signalling and for the development of normal granule 
content, was also demonstrated and the possibility that reduced NFE2 expression could 
contribute to the functional abnormalities was supported by the finding that RUNX1 could bind 
the NFE2 promoter and activate its expression in primary megakaryocytes.38 
Further insights into the mechanisms underlying FPD/AML have been gained from expression 
profiling of platelets from a patient with FPD/AML and a splice site defect in RUNX1 which 
revealed 298 genes that were significantly downregulated when compared with wild-type 
platelets. Of these, MYL9, encoding myosin light chain-9 (MLC) regulatory polypeptide, 
showed the greatest downregulation, correlating with the reduction in agonist-induced MLC 
phosphorylation observed in the patient¶V platelets.39 MYL9 was subsequently demonstrated 
to be a transcriptional target of RUNX1, suggesting that the thrombocytopenia associated with 
RUNX1 defects is at least partly explained by reduced MYL9 expression and the resulting 
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decrease in MLC phosphorylation.40 Further studies from the same group showed that in 
addition to MYL9, several other genes which were downregulated in platelets from the 
FPD/AML patient were direct targets for transcriptional regulation by RUNX1, contributing to 
the functional abnormalities observed in the FPD/AML platelets. Thus, the decreased agonist-
induced production of 12-hydroxyeicosatetraenoic acid  that was observed in the FPD/AML 
platelets was explained by the downregulation of ALOX12, the gene encoding 12-
lipoxygenase.41 Similarly, a decrease in platelet pleckstrin phosphorylation and protein kinase 
C-ș3.&-șJHQHPRKCQ) was explained by the finding that PRKCQ is regulated by RUNX1 
in megakaryocytes.42 Likewise, platelet factor 4 (PF4) was found to be a transcriptional target 
of RUNX1, explaining the PF4 deficiency associated with RUNX1 haplodeficiency.43 More 
recently, RUNX1 was demonstrated to activate PF4 synergistically with the transcription 
factors CBFE, ETS-1 and FLI-1 during megakaryocytic differentiation.44 
Two preliminary studies  reported that the genes encoding RAB1B (RAB1B), a low molecular 
weight GTPase that is essential for vesicle transport between the endoplasmic reticulum and 
the Golgi apparatus, and Pallidin (PLDN), which is involved in granule vesicle biogenesis, 
were both downregulated in RUNX1 haplodeficiency, and shown to be direct targets for 
RUNX1 regulation, providing possible mechanisms for the defective granule biogenesis and 
secretion observed in RUNX1 deficiency.45,46 
4.1.4 Association of RUNX1 defects with haematological malignancy 
The incidence of myelodysplastic syndrome (MDS) or AML in families with FPD/AML is greater 
than 40% and the median age of onset is 33 years.36 The observation that dominant-negative 
variants of RUNX1 are associated with a higher risk of haematological malignancy than 
defects causing haploinsufficiency of RUNX1 suggests that RUNX1 dosage contributes to the 
risk of malignancy.47 The identification of RUNX1 defects predicting haploinsufficiency of 
RUNX1 in members of three families diagnosed with a mild bleeding tendency characterised 
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predominantly by a failure in dense granule secretion, none of whom had a personal or family 
history of haematological malignancy, would support this observation.48 
FPD/AML provides a useful model in which to study the alterations in haematopoiesis as a 
result of a germline RUNX1 defect and the subsequent progression to leukaemia. Comparison 
of haematopoiesis in two families with FPD/AML, one without AML and a mutation causing 
haploinsufficiency of RUNX1 (p.R139X) and a second with a strong predisposition to AML and 
a dominant negative RUNX1 defect (p.R174Q) revealed an increased clonogenic potential of 
immature progenitor cells bearing both defects. This correlated with markedly reduced 
expression of the nuclear receptor NR4A3 in CD34+ cells from patients with the p.R139X 
variant but undetectable NR4A3 expression in cells from patients with the p.R174Q variant. 
Given that NR4A3 is a transcriptional target of RUNX1, and its deficiency predisposes to AML 
in mice, it has been suggested that its downregulation can increase the pool of cells that are 
susceptible to secondary events predisposing to leukaemia.49 Interestingly, the potential for 
treatment of FPD/AML was recently demonstrated when the in vitro correction of a p.Y260X 
RUNX1 defect by gene targeting in induced pluripotent stem cells (iPSCs) derived from two 
affected patients produced a cell line that exhibited normal megakaryopoiesis.50 
4.2 GATA-1 
4.2.1 Structure and function of GATA-1 
GATA binding protein-1, or GATA-1 (previously known as GF1), belongs to the GATA family 
of transcription factors. It is highly expressed in erythrocytes, megakaryocytes, mast cells and 
eosinophils, and promotes differentiation by activating lineage specific genes associated with 
megakaryopoiesis and erythropoiesis, and silencing genes associated with undifferentiated 
proliferative states.51 The GATA1 gene lies on the X-chromosome, at position Xp11.23, and 
comprises 6 exons that encode a 413 amino acid protein which contains two conserved zinc 
finger domains (Fig. 3). Two splice variants of GATA1 are normally detected in peripheral 
blood RNA, a full length form, and a shorter GATA1s isoform derived from skipping of exon 
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2.52 The C-terminal zinc finger (CF) interacts with DNA through the canonical (A/T)GATA(A/G) 
consensus sequence and is essential to the function of GATA-1 in regulating 
megakaryopoiesis and erythropoiesis. GATA DNA binding sites have been identified in 
several megakaryocyte-specific genes including those encoding GPIbD, GPIbE, GPIIb, GPIX 
and GPVI.53±56 The N-terminal zinc finger (NF) is required to stabilize DNA interactions by 
binding to non-canonical GATC and palindromic ATC(A/T)GATA(A/G) motifs.57±59 It also binds 
to co-regulators, including zinc finger protein, Friend of GATA1 (FOG1; also known as ZFPM1) 
which is required for activation and repression of the majority of GATA1-regulated genes.60±62 
Through LIM-only protein (LMO2), the NF of GATA1 also binds to the oligomeric TAL1 
complex comprised of E2A, LMO2, Ldb1 and TAL1 at sites of transcriptional activation, and 
LMO2, Ldb1 and TAL1 have all been demonstrated to be essential for megakaryopoiesis and 
erythropoiesis.63±67 GATA-1 also possesses an N-terminal transactivation domain which 
interacts with RUNX1. In addition to expressing full length GATA-1, normal haematopoietic 
cells also express a shorter isoform termed GATA1s which lacks the N-terminal transactivation 
domain. The regions of GATA-1 that make contact with DNA, FOG1 and LMO2 have all been 
defined at a structural level.64,68,69 
Targeted disruption of murine Gata1 has shown that it is critical for the terminal differentiation 
of erythroid and megakaryocytic cells, while conditional knockout of Gata1, which results in 
selective loss of megakaryocyte GATA-1, leads to decreased polyploidization and a lack of 
cytoplasmic maturation in the megakaryocytes.70±72 The interaction of GATA-1 with FOG1 is 
essential for erythropoiesis. This is highlighted by the finding that both FOG1 and GATA-1 null 
mice demonstrate embryonic lethality due to severe anaemia.51 
4.2.2 Germline GATA1 defects and platelet dysfunction  
The first germline mutation described in GATA1 was a missense defect predicting a p.V205M 
amino acid substitution in GATA-1, which was identified in two half-brothers with severe 
thrombocytopenia and pronounced anaemia.73 Bone marrow from the affected patients 
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displayed dyserythropoiesis and an abundance of abnormally small, dysplastic 
megakaryocytes. The platelets also showed dysplastic changes including a paucity of 
granules. Interestingly, the mother of the two boys had mild thrombocytopenia, most likely as 
a result of silencing of more wild-type than variant GATA1 alleles during X-chromosome 
inactivation.73 Due to the low platelet counts in the patients, it was not possible to perform 
platelet aggregation studies. The mutation occurs in the NF domain and was demonstrated to 
cause a reduction in the affinity of GATA-1 for FOG1. Since this report, several other GATA1 
defects, primarily affecting amino acids in the NF domain, and all of which decrease the affinity 
of GATA-1 for FOG1, have been described. The clinical presentations of the patients vary 
considerably according to the amino acid substituted, and different amino acid substitutions at 
the same position can lead to considerable variation in phenotypic expression. Thus, while the 
p.V205M, p.G208R and p.D218Y amino acid substitutions result in severe thrombocytopenia 
with pronounced anaemia, p.G208S and p.D218G substitutions result in milder clinical 
phenotypes characterised by moderate thrombocytopenia with minimal or no anaemia.73±77 
The effects of the p.D218G variant, which was associated with macrothrombocytopenia and 
mild dyserythropoiesis without anaemia, were studied extensively in platelets from the affected 
patients.74 RNA analysis revealed significantly reduced expression of the GATA-1 target 
genes GP1BB, and GP9, but expression of the GsD gene, GNAS1, which is not a direct GATA-
1 target, but the expression of which is up-regulated in the later stages of megakaryocytic 
maturation, was also reduced, suggesting incomplete megakaryocyte maturation. The finding 
that ITGB3 (encoding E3 integrin) expression was normal would support this suggestion since 
it is expressed early during megakaryocyte differentiation. Flow cytometry revealed the 
presence of a population of platelets that showed a wide distribution in size and glycoprotein 
expression, varying from giant platelets that were up to 5 times the size of normal platelets 
that showed reduced GPIbDbut normal GPIIIa levels to immature platelets that lacked almost 
all of the membrane glycoprotein receptors tested including GPIbD, GPIbE, GPIIIa, GPIX and 
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GPV. The platelets showed an impaired agglutination response to ristocetin that was GPIb 
dependent, as well as impaired aggregation in response to collagen.74   
While most of the mutations identified in the NF domain of GATA-1 decrease the affinity of 
GATA-1 for FOG1, substitution of arginine 216, which lies on the DNA binding face of the NF, 
with glutamine, resulted in a GATA-1 variant that has normal affinity for GATA sites, but 
decreased affinity for palindromic sites without disrupting interactions with its co-factor 
FOG1.78 The variant, which was associated with a disorder previously referred to as X-linked 
thrombocytopenia with E-thalassemia was originally found to result in platelets that aggregate 
normally,79 though subsequent platelet function studies in a patient with the same variant 
revealed reduced aggregation in response to collagen, and decreased phosphorylation of 
GPVI signalling proteins.80 Although the majority of patients reported with the p.R216Q variant 
are male, females may have mild to moderate symptoms which are related to the proportion 
of cells containing the mutated GATA1 allele on the active X chromosome.81 The p.R216Q 
variant was also identified as the underlying cause of a mild bleeding disorder in a family with 
an X-linked form of Gray Platelet Syndrome (GPS) which was characterised by 
thrombocytopenia and the absence of D-granules from platelets.82 
A splice site defect in GATA-1 (c.332G>C; p.V74L) that results in synthesis of only the short 
GATA1s isoform, has been described in seven male members of a Brazilian family affected 
by X-linked anaemia with or without neutropenia.83 This suggests that the GATA1s isoform is 
not sufficient to support normal erythropoiesis, in contrast to the findings in a mouse model in 
which Gata1 was targeted to introduce alleles that solely generated GATA1s.84 Whereas 
somatic mutations that result in the formation of the GATA1s isoform have been found in 
subjects with Down syndrome acute megakaryoblastic leukaemia, none of the patients with 
the germline defect had leukaemia. The female carriers of the mutation were unaffected. 
Platelets from two of the affected male patients showed impaired aggregation in response to 
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ADP, epinephrine and collagen, and ultrastrutural analysis revealed round platelets with a 
reduced number of D- and dense granules.83  
4.3 GFI1b 
4.3.1 GFI1b structure and function 
The zinc finger containing growth factor independent 1B transcription repressor, or GFI1b, is 
crucial for normal haematopoiesis and an essential transcriptional regulator of erythroid and 
megakaryocytic development.85 Thus, GFI1b controls human erythroid and megakaryocytic 
differentiation at the megakaryocyte-erythroid progenitor stage, by binding to and repressing 
expression of type III transforming growth factor receptor gene.86 Deletion of the Gfi1b gene 
is embryonic lethal in mice, and the Gfi-1b embryos show delayed maturation of primitive 
erythrocytes, while the fetal liver contains erythroid and megakaryocytic precursors which 
have been arrested in their development.87 GFI1b is highly expressed in HSCs, and its loss in 
mice leads to significantly increased HSC numbers in bone marrow and peripheral blood, 
which show decreased expression of CXCR4 and vascular cell adhesion protein-1 (VCAM-1) 
which are both required to retain HSCs in the endosteal niche. This has led to the suggestion 
that GFI1b regulates the dormancy of HSCs and their mobilization to peripheral blood.88  
Located on chromosome 9q34.13, the GFI1B gene comprises 11 exons encoding a 330 amino 
acid protein that has six C2H2-type zinc fingers at its C-terminus, of which zinc fingers 3 to 5 
are essential for binding to their consensus recognition sequence TAAATCAC(A/T)GCA in 
DNA.89±91 The N terminal 20 amino acids encompass a SNAG (Snail/Gfi1) domain that is 
present in other transcriptional repressors and required for nuclear localisation and to mediate 
interactions with other corepressors (Fig. 4).92   
4.3.2 GFI1B defects and platelet dysfunction  
A small number of germline GFI1B defects have been described in patients with platelet 
disorders (Fig. 4). The first of these was identified in a four generation Caucasian family which 
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was first described in 1976, and which displayed an autosomal dominant bleeding disorder of 
variable severity.93,94 The disorder was characterised by moderate macrothrombocytopenia 
and red cell anisopoikilocytosis. In addition, platelets from affected family members displayed 
an absence of aggregation to collagen, as well as variable responses to other platelet 
DJRQLVWV7KHSDWLHQWV¶SODWHOHWVVKRZHGQRUPDOOHYHOVRIVXUIDFHJO\FRSURWHLQVEXWP-selectin 
expression and pac-1 binding were reduced following activation with ADP. Linkage analysis 
and massively parallel sequencing identified the underlying genetic defect as a single 
nucleotide insertion in GFI1B that introduced a frameshift mutation in the fifth zinc finger of 
GFI1B (c.880-881insC; p.H294fsX307), which was predicted to result in loss of the invariant 
histidine residues considered essential to stabilize the zinc ion that is required for correct 
folding of the DNA binding domain. The mutation was shown to alter the transcriptional activity 
of GFI1B, and was associated with aberrant expression of the D-granule proteins, P-selectin 
and fibrinogen as well as membrane glycoproteins, GPIIIa and GPIbD. In addition, there was 
a reduction in the D-granule content of platelets similar to that observed in platelets from 
patients with GATA1 defects.94   
A second GFI1B defect was identified in a family with an autosomal dominant form of GPS.95 
Affected members of the family, which was originally described in 1968, suffered from 
moderate to severe bleeding tendencies associated with macrothrombocytopenia, and 
platelets which showed a marked reduction in platelet D-granule content, and a reduction in 
PF4 and E-thromboglobulin levels.95,96 Examination of bone marrow from an affected family 
member revealed an increase in the number of dysplastic megakaryocytes, and emperipolesis 
was a common feature. Linkage analysis and subsequent sequencing of GFI1B as a candidate 
gene, led to the identification of a nonsense defect that predicted production of a truncated 
GFI1B lacking the 44 carboxyterminal amino acids (c.859C>T; p.Gln287*). The mutated 
GFI1B mRNA was stably expressed in CD34+ progenitor cells from patients and the variant 
was shown to inhibit the repression activity of wild-type GFI1B in a dominant-negative manner. 
Immunophenotyping of platelets from several family members revealed reduced GPIbD, CD41 
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and CD61 as well as strong expression of CD34 on platelets from the patients when compared 
to control platelets.95 Interestingly, a preliminary study has suggested that platelet CD34 
expression may be a surrogate marker for GFI1B defects since it was not observed in platelets 
from patients with GATA1, FLI1, or RUNX1 mutations.97  
The location of defects in GFI1B appears to be clinically relevant. This was highlighted by the 
preliminary report of a third missense GFI1B defect in the region encoding the first zinc finger 
domain (c.503G>T p.C168F) which was identified in two unrelated families and characterised 
by the presence of large platelets with a normal granule content on the blood film, moderate 
thrombocytopenia and the absence of any platelet aggregation abnormality. However, 
individuals with the p.C168F defect had significantly milder bleeding symptoms than those 
with the c.880-881insC defect and the variant also had less impact on transcriptional activity 
than the c.880-881insC defect.98 
4.4 ETS transcription factors 
Named after its founding member, which was identified in E26 avian retrovirus, the E26-
transformation specific (ETS) protein family comprises 29 transcription factors that are 
expressed in different tissues and regulate gene expression in a diverse array of cellular 
activities. They all share a common 85 amino acid DNA binding, or ETS, domain that interacts 
with DNA sequences that are centred on a GGAA/T motif (Fig. 5).99 The focus here will be on 
two members of the family, defects in which have been described in patients with platelet 
disorders.  
4.4.1 FLI1 
Friend Leukaemia virus integration 1, or FLI1, is expressed at high levels in megakaryocytic 
progenitors and plays a major role in megakaryopoiesis, regulating the expression of multiple 
megakaryocyte-specific genes, both early and late in megakaryopoiesis.100 It seems to exert 
its effects in concert with a second ETS transcription factor, GA binding protein transcription 
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factor, D subunit (GABPA), with GABPA preferentially binding to the ETS elements of genes 
expressed during the early stages of megakaryopoiesis and the ratio of FLI1/GABPA 
expression levels increasing in the later stages of megakaryocyte development. Thus, studies 
with Fli-1-/- and GABPD-/- mice have shown that GABPA deficient megakaryocytes have 
impaired expression of early megakaryocyte-specific genes such as MPL and DIIb, while Fli1-
/-
 deficient megakaryocytes demonstrated reduced expression of genes expressed during the 
late stages of MK maturation such as GPIbD, GPIX and PF4.101 The human FLI1 gene is 
localised on chromosome 11q23.3-24, and comprises nine exons encoding a protein of 452 
amino acids, which is expressed primarily in haematopoietic cells and comprises a conserved 
ETS domain and an N-terminal pointed (PNT) transactivation domain.102   
Homozygous deletion of Fli1 in mice is embryonic lethal, with the embryos displaying 
intracranial haemorrhaging, while the heterozygous mice are viable, fertile and appear normal 
and have a normal tail bleeding time. Examination of megakaryopoiesis from HSCs revealed 
an increase in the relative number of megakaryocyte progenitor cells in Fli1 -/- mice compared 
to wild-type and heterozygous mice, and there was an increase in the number of colonies 
containing undifferentiated megakaryocytes.103 In humans, transcriptional activation of FLI1 
by chromosomal translocation of the genetic region encoding the DNA binding domain of FLI1 
to the EWS locus on chromosome 22 leads to Ewings sarcoma.104  
4.4.2 Chromosomal defects involving FLI1 
Partial deletion of chromosome 11 in a region that includes FLI1 results in two syndromes 
which share many features, Jacobsen syndrome and Paris-Trousseau syndrome.105±107 These 
have an estimated prevalence of 1 in one million and the majority are due to de novo deletions 
that vary in size up to 20 Mb, with the breakpoints occurring in the region of 11q23.3.108,109 The 
patients usually have neonatal thrombocytopenia, with an increased number of 
megakaryoctyes in the bone marrow and dysmorphic facial features, and additional 
abnormalities affecting the heart, kidney, gastrointestinal tract, genitalia and central nervous 
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system. Skeletal abnormalities can also occur. The two syndromes differ in severity, with 
Paris-Trousseau syndrome being characterised primarily by the thrombocytopenia which may 
be accompanied by other features, while Jacobsen syndrome is more complex. The 
differences in clinical expression are likely to reflect the size and location of the chromosomal 
breakpoint in the patients. Paris Trousseau syndrome is characterised by the presence in the 
circulation of a subpopulation of large platelets containing abnormally large fused D-granules 
and dysmegakaryocytopoiesis in the bone marrow.110 
4.4.3 Germline FLI1 defects causing platelet dysfunction   
Germline defects in FLI1 have also been described (Fig. 5). Thus, two defects predicting 
amino acid substitutions in the ETS domain (p.Arg337Trp and p.Tyr343Cys) and associated 
with reduced transcriptional activity of the protein, were identified in families with a bleeding 
diathesis which was characterised predominantly by a reduction in dense granule secretion.48 
One of these, the p.Tyr343Cys variant, was also associated with mild thrombocytopenia, 
alopecia and eczema in affected family members while the p.Arg337Trp variant was 
associated with alopecia, eczema or psoriasis and recurrent viral infections. The same study 
identified a 4-bp frameshift deletion (c.992-995del; p.Asn331Thrfs*4) in two members of a third 
family, who had symptoms of excessive bleeding characterised by a significant reduction in 
dense granule secretion and thrombocytopenia.48  
Recently, a homozygous c.970C>T FLI1 defect predicting a p.Arg324Trp substitution in the 
ETS domain was reported in members of a consanguineous family showing autosomal 
recessive inheritance of a bleeding disorder that mimicked Paris-Trousseau Syndrome, and 
was associated with the persistence of MYH10 expression, a recognised biomarker for FLI1 
defects.111 The disorder was characterised by moderate thrombocytopenia, absence of 
collagen-induced platelet aggregation and the presence of abnormally large D-granules in up 
to 5% of platelets, but none of the other features of Paris-Trousseau syndrome. The 
p.Arg324Trp variant was shown to cause a defect in transcription and a reduction in 
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expression of the FLI1 target genes GP6, GP9 and ITGA2B.111 The findings of these studies 
suggest that loss of FLI1 is the likely explanation for the thrombocytopenia associated with 
Paris-Trousseau syndrome.48,111  
There has also been a preliminary report of a FLI1 defect resulting in a p.Arg144Gln 
substitution in the PNT domain of FLI1. This was the first defect to be identified in the pointed 
domain, and was identified in a patient with mild thrombocytopenia without any bleeding 
symptoms. Again, the presence of the p.R144Q variant was associated with MYH10 
expression in platelets.112 
4.4.4 ETV6  
Ets variant 6 (ETV6), also known as TEL, is widely expressed in all tissues. It was originally 
cloned in 1994 as the fusion gene resulting from a t(5;12) translocation that occurred in the 
malignant cells of a patient with chronic myelomonocytic leukaemia. The translocation led to 
fusion of PDGFRB (encoding platelet-derived growth factor receptor E) located on 
chromosome 5q31 with a previously unknown gene derived from chromosome 12p12, which 
was originally named TEL, but later renamed ETV6.113 
Like GFI1b, ETV6 acts as a transcriptional repressor that requires dimerisation to exert 
repression, and which is regulated by self-association and auto-inhibition.114,115 It also 
modulates the activity of other ETS transcription factors, including FLI1.116 Knockout studies 
have shown that deletion of Etv6 is embryonic lethal in mice, and essential for definitive 
haematopoiesis in the bone marrow.117,118 Conditional knockout of Etv6 established it as a 
selective regulator of HSC survival as was evidenced by the loss of HSCs from the adult bone 
marrow following inactivation of Etv6. Following commitment of the HSCs, absence of Etv6 
has little effect apart from the impaired maturation of megakaryocytes.119  
ETV6 comprises 8 exons and encodes a 452 amino acid protein with three functional domains, 
a C-terminal ETS domain that binds DNA, a highly conserved N-terminal PNT domain which 
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mediates homo and heterodimerisation, and is required for nuclear localisation of the protein, 
and a central regulatory domain (amino acids 127-331) which is located between the PNT and 
ETS domains of the protein (Fig. 5). The transcriptional repression activity has been mapped 
to the PNT and central regulatory domains. Repression by the PNT domain is mediated by 
interaction with the transcriptional repressor lethal(3) malignant brain tumour-like protein 1 
(L3MBTL1), a polycomb group protein,120 while repression by the central inhibitory domain is 
mediated via corepressor complexes such as SMRT, mSin3A and N-CoR, which recruit 
histone deacetylases (HDACs) and can be relieved by HDAC inhibition.121,122 
4.4.5 Germline ETV6 defects and platelet disorders  
Since its original description, several somatic alterations involving ETV6 have been described 
in leukaemia and other haematological malignancies. More recently, there have been three 
reports of germline defects in ETV6 in patients with autosomal dominant thrombocytopenia 
and a predisposition to haematologic malignancy (Fig. 5). 
Zhang et al123 identified missense defects in ETV6 in three unrelated families with autosomal 
dominant thrombocytopenia, and predisposition to a diverse range of haematologic 
malignancies, including MDS, pre-B cell ALL, multiple myeloma and CMLL.123 Two of the 
defects predicted amino acid substitutions in the ETS DNA binding domain. One of these, 
p.Arg399Cys affects an amino acid that directly contacts with DNA at the ETS binding element 
GGA(A/T) (the consensus is a 9bp sequence with the core GGA(A/T) motif), while the second, 
p.Arg369Gln, involved an amino acid that forms a hydrogen bond with Arg414 which is 
involved in electrostatic interactions with DNA so the substitution by Gln could destabilise the 
ETS domain, or interfere with the interaction of Arg 414 with DNA. A third missense defect 
predicted a p.Pro214Leu substitution in the central inhibitory domain.  Interestingly, all three 
defects occurred in regions of ETV6 that are hotspots for somatic mutation in malignancies. 
The p.Arg369Gln and p.Arg399Cys variants both abrogated binding to DNA, and expression 
studies in HeLa cells revealed altered subcellular localisation of all three variants, with the 
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p.Pro214Leu variant mainly confined to the cytoplasm, and the p.Arg369Gln and p.Arg399Cys 
variants showing reduced nuclear localisation. All three variants also decreased transcriptional 
repression mediated by wild-type ETV6 in a dose-dependent manner. Proliferation of CD34+ 
cells expressing the three variants was markedly reduced in all cases, providing an 
explanation for the thrombocytopenia observed in the patients.123  
Noetzli et al (2015) described three further unrelated families with ETV6 variants which were 
associated with autosomal dominant thrombocytopenia, a high erythrocyte MCV, and a 
predisposition to leukaemia.124 Two families harboured the previously identified p.Pro214Leu 
variant, while the third harboured a c.1252A>G transition which caused a frameshift that 
resulted in exon skipping and partial deletion of the ETS domain (p.Asn385Val fs*7), and 
production of a truncated protein, which could be detected in overexpression studies, but not 
in platelets. Interestingly, not all of the mutated RNA was alternatively spliced and a proportion 
was translated to give rise to a p.Arg418Gly substitution in the ETS domain. Platelets from 
affected patients appeared normal, though some had elongated D-granules and there were 
hypolobulated megakaryocytes and abnormal RBC precursors present in the bone marrow. 
Further characterization of the variants revealed reduced transcription repression activity, and 
delayed and decreased maturation of megakaryocytes when cultured from CD34+ cells. Like 
the p.Pro214Leu variant, the p.Arg418Gly variant was concentrated in the cytoplasm of 
megakaryocytes, and both formed dimers with wild-type ETV6, reducing nuclear translocation 
of the wild-type protein in a dominant negative manner.124    
Two further ETV6 variants were identified in two families with thrombocytopenia and ALL. One 
of these predicted a p.Leu349Pro substitution in the ETS domain, and the second was a 5 
base pair deletion causing a frameshift and resulting in production of a truncated protein 
p.N385fs. Again, both variants displayed a reduced ability to repress expression of genes 
normally suppressed by ETV6 (PF4 and MMP3), and a failure to promote expression of EGR1 
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and TRAF1. Both variants were confined to the cytoplasm and were not detected in the 
nucleus.125 
Finally, a single base insertion ETV6 has been reported in abstract form. The c.601-602insC; 
p.L201Pfs*15 defect, which was identified alongside another case of the c.641C>T 
p.Pro214Leu defect, also demonstrated reduced repressive activity.126 
Conclusions 
The investigation of patients with unexplained inherited platelet disorders has allowed the 
identification of a subgroup of patients harbouring defects in one of five transcription factors, 
FLI1, RUNX1, GATA1, GFI1B and ETV6, all of which serve important regulatory roles in 
megakaryopoiesis and platelet production. These defects usually result in haploinsufficiency, 
or affect functionally relevant domains of the transcription factors affecting their interactions 
with co-activators and or target DNA sequences. In most, but not all, cases the transcription 
factor defects are also associated with mild thrombocytopenia. These disorders vary 
considerably, making their diagnosis difficult when based solely on the clinical and phenotypic 
features of the patient. However, the presence of MYH10 in platelets from affected patients is 
a surrogate marker for FLI1 and RUNX1 defects and CD34 expression may be a marker for 
GFI1B defects. A history of haematologic malignancy may suggest a RUNX1 or ETV6 defect 
which will have prognostic implications for the patient, and abnormal red cell features which 
may be accompanied by anaemia would suggest a GATA1 or a GFI1B defect. Ultimately, the 
presence of a transcription factor defect should be confirmed by DNA sequencing and any 
candidate defects should be investigated further to confirm that they are dysfunctional.    
Looking to the future, as more patients with unexplained bleeding disorders are investigated 
by whole exome or genome analysis, we anticipate the identification of further novel defects 
in the transcription factors that are involved in megakaryopoiesis and thrombopoiesis, and 
their co-activators. Characterisation of these defects and of the genes that are differentially 
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expressed as a result, will yield insights into the molecular and cellular mechanisms involved 
in megakaryopoiesis and in platelet production and function, and has the potential to deliver 
strategies for treatment of the bleeding symptoms in affected patients. Furthermore, the use 
of gene editing technologies to correct transcription factor defects in iPSCs offers a potential 
therapeutic approach for those patients where the defects are associated with haematologic 
malignancy.   
 
Practice points 
x Germline defects in the genes encoding the transcription factors RUNX1, GATA-1, 
FLI1, GFI1b and ETV6 account for a significant number of patients with previously 
unexplained platelet function defects. 
x Transcription factor defects tend to occur in regions of the transcription factor genes 
that encode functional domains and affect the interaction of the transcription factor with 
target DNA sequences and or co-activators.  
x Persistence of MYH10 expression in platelets is a useful biomarker for the presence 
of FLI1 and RUNX1 defects and platelet CD34 expression may be a surrogate marker 
for GFI1B defects. 
x Transcription factor defects in RUNX1 and ETV6 can also be associated with an 
inherited predisposition to haematological malignancies and may therefore have 
prognostic implications.  
Research agenda  
x Investigation of further cases with unexplained inherited platelet disorders is likely to 
reveal novel defects in other transcription factors that are required for haematopoiesis.  
x Identification of the genes that are differentially regulated in patients with platelet 
disorders as a result of transcription factor defects will yield insights into the molecular 
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and cellular mechanisms governing platelet production and function, and may identify 
strategies to allow the in vitro production of platelets for therapeutic use.     
x Correction of transcription factor gene defects in induced pluripotent stem cells from 
affected patients offers a potential treatment for the haematologic malignancies 
associated with certain transcription factor defects.  
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Figure legends 
Figure 1.  
Relative expression of the transcription factors GATA1, ETV6, FLI1, RUNX1 and GFI1B 
across eight cell types derived from haematopoietic stem cells (HSC) in the bone marrow. 
MPP multipotent progenitor; CMP common myeloid progenitor; CLP common lymphoid 
progenitor; GMP granulocyte-monocyte progenitor; EB erythroblast; MEP megakaryocyte 
erythrocyte progenitor; MK megakaryocyte. The riverplot was generated using the Blueprint 
Progenitors dataset and the online tool available at http://blueprint.haem.cam.ac.uk/21 
Figure 2.  
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Schematic representation of RUNX1. Different functional domains are highlighted by 
horizontal black bars and the locations of the PY and VWRPY motifs are also indicated. TD: 
transactivation domain; ID: inhibitory domain; NLS: nuclear localization signal; NMTS: nuclear 
matrix targeting signal.  The locations of variants identified in patients with platelet defects and 
referred to in the text are shown. Intronic mutations, predicted to interfere with splicing of the 
RUNX1 RNA, are shown in italics. Variants shown in boxed were identified in families with no 
history of haematological malignancy, while the remainder were identified in families with 
FPD/AML.  
Figure 3.  
Schematic representation of GATA-1. Different functional domains are highlighted by 
horizontal black bars and the locations of the PY and VWRPY motifs are also indicated. TD: 
transactivation domain; NF: N-terminal zinc finger; CF: C-terminal zinc finger; FOG1: Friend 
of GATA-1; LMO2: LIM-only protein. The locations of variants identified in patients with platelet 
defects and referred to in the text are shown. The splice site variant in exon 2 that results in 
synthesis of the GATA-1s isoform which lacks the N terminal 84 amino acids is indicated in 
italics.   
Figure 4.  
Schematic representation of GFI1b showing the location of variants identified in patients with 
platelet function disorders. The domains required for DNA binding and nuclear localisation of 
GFI1b are indicated by horizontal black bars. ZF: Zinc finger domain; SNAG: Snail/Gfi1 
domain. 
Figure 5. 
Schematic representation of the ETS family members FLI1 (upper panel) and ETV6 (lower 
panel) showing the domain structure of the proteins and the locations of variants identified in 
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patients with platelet dysfunction disorders. The domains involved in binding to DNA, and in 
activation and repression of transcription are indicated by horizontal black bars. PNT: pointed 
domain; ETS: E26 transformation specific domain.  
 
